GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Cirrhosis Liver/Early Hepatic Encephalopathy After TIPS Is Associated With Reduced Survival

Early Hepatic Encephalopathy After TIPS Is Associated With Reduced Survival

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2025

Quick Answer

Yes, early hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) placement is strongly associated with reduced survival. This conclusion is supported by a large multicenter analysis involving 1,356 patients with cirrhosis who underwent TIPS placement across eight German tertiary centers.


Yes, early hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) placement is strongly associated with reduced survival. This conclusion is supported by a large multicenter analysis involving 1,356 patients with cirrhosis who underwent TIPS placement across eight German tertiary centers. The study followed patients longitudinally for up to 30 months to evaluate HE occurrence and survival outcomes, providing critical insights into the timing and prognostic significance of HE.

### Key Findings:

1. **Impact of Early HE on Survival**:

  • Early HE, defined as episodes occurring within 30 days after TIPS insertion, was strongly associated with impaired survival compared to patients who did not develop HE.
  • The negative prognostic impact of HE was driven entirely by these early episodes, highlighting their clinical importance.

2. **Late HE Not Harmful**:

  • HE occurring after 30 days post-TIPS did not worsen survival, suggesting that the timing of HE is crucial in determining its prognostic significance.

3. **Landmark Analysis Confirmation**:

  • Thirty- and ninety-day landmark analyses confirmed early HE as an independent predictor of mortality, reinforcing its role in survival outcomes.

4. **Severity of HE**:

  • The survival outcomes did not differ significantly between patients with grade 2 HE versus grade 3–4 HE. This indicates that the occurrence of early HE itself, rather than its severity, is the critical factor impacting survival.

5. **Pre-TIPS HE and Survival**:

  • A history of HE before TIPS was an independent predictor of worse post-TIPS survival. Patients who had both pre-TIPS HE and early post-TIPS HE demonstrated the poorest survival outcomes, identifying them as the highest-risk group.

6. **Risk Factors for Early HE**:

  • Several factors increased the risk of developing early HE, including:
  • Older age.
  • Impaired renal function.
  • Hyponatremia.
  • Higher MELD (Model for End-Stage Liver Disease) score.
  • Prior history of HE.

7. **Portal Pressure Reduction**:

  • The hemodynamic response to TIPS, specifically portal pressure reduction, was similar regardless of HE development, suggesting that early HE reflects overall patient vulnerability rather than being a direct cause of mortality.

### Clinical Implications:

  • **Monitoring and Follow-Up**:
  • Patients with pre-TIPS HE or early post-TIPS HE require intensified monitoring and follow-up to address their heightened risk of mortality.
  • **Prognostic Scores**:
  • Current prognostic scores like MELD and FIPS do not fully account for the timing of HE, indicating the need for improved tools to assess risk in patients undergoing TIPS.
  • **Global Vulnerability Marker**:
  • Early HE may serve as a marker of global patient vulnerability rather than a direct cause of death, emphasizing the importance of identifying and managing underlying factors contributing to HE.

### Conclusion:

Early HE after TIPS is a critical prognostic factor associated with reduced survival. Identifying high-risk patients, such as those with pre-TIPS HE or early post-TIPS HE, and implementing tailored management strategies are essential to improve outcomes after TIPS placement.

Related Q&A

POCUS-Guided AKI Management in Cirrhosis: Hepatology | July 2026

Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...

A Novel Pro-Resolving Target (Annexin A1) for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Distal Esophageal Varices in Fontan Circulation: Hepatology | May 2026

Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...

Annexin A1-A Novel Pro-Resolving Target for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Simvastatin Improves Survival After Variceal Bleeding in Cirrhosis: AJG | July 2026

Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...

Pre-Emptive CRRT Improves Outcomes in ALF with Cerebral Oedema: AP&T | June 2026

Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer